Lipid Infiltration in the Parotid Glands: A Clinical Manifestation of Metabolic Syndrome

Abstract

Background:

The clinical features of lipid infiltration in the parotid glands (LIPG) have not been studied. Monitoring of atomic-bomb survivors for late effects of radiation exposure has provided the opportunity to review the clinical findings of LIPG.

Methods:

A total of 992 atomic-bomb survivors in Nagasaki, Japan underwent lachrymal and salivary secretion tests and anthropometric, biochemical, and abdominal ultrasonographic examinations between 2002 and 2004. Among 465 subjects who had reduced tear and/or salivary excretion, 176 subjects took a salivary magnetic resonance imaging (MRI) examination.

Results:

LIPG was detected in 53 of the 176 subjects who had salivary MRI. LIPG cases showed a preponderance of females and fatty liver compared with the subjects without LIPG. Age-and-sex-adjusted regression analysis revealed that body mass index (BMI), low-density lipoprotein cholesterol, triglycerides, hemoglobin A1c, and C-reactive protein were higher, whereas high-density lipoprotein cholesterol and adiponectin were lower, in the subjects with LIPG. Multivariate logistic regression analysis showed that BMI and fatty liver were mutually associated with LIPG independently from radiation dose.

Conclusions:

LIPG associated with BMI, fatty liver, and coronary risk factors was a clinical manifestation of metabolic syndrome.

Key words

sicca syndrome - fatty liver - coronary risk factors

• References

• 1 Akahoshi M, Amasaki Y, Soda M et al. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens Res 2001; 24: 337-343
• 2 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553
• 3 Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83
• 4 Atomic Bomb Casualty Commission . Research plan for joint ABCC-NIH Adult Health Study in Hiroshima and Nagasaki, Japan. ABCC Technical Report. 1962; 11-62
• 5 Baba T, Amasaki Y, Soda M et al. Fatty liver and uric acid levels predict incident coronary heart disease but not stroke among atomic bomb survivors in Nagasaki. Hypertens Res 2007; 30: 823-829
• 6 Committee to Evaluate Diagnostic Standards for Metabolic Syndrome . Definition and the diagnostic standard for metabolic syndrome – Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. Nippon Naika Gakkai Zasshi 2005; 94: 794-809
• 7 Goldman JA, Julian EH. Pseudo-Sjogren syndrome with hyperlipoproteinemia. JAMA 1977; 237: 1582-1584
• 8 Hayashi T, Boyko EJ, Leonetti DL et al. Visceral adiposity and the prevalence of hypertension in Japanese Americans. Circulation 2003; 108: 1718-1723
• 9 Hida A, Akahoshi M, Takagi Y et al. Prevalence of Sjogren syndrome among Nagasaki atomic bomb survivors. Ann Rheum Dis 2008; 67: 689-695
• 10 International Expert Committee . International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-1334
• 11 Iwashima Y, Katsuya T, Ishikawa K et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-1323
• 12 Izumi M, Hida A, Takagi Y et al. MR imaging of the salivary glands in sicca syndrome: comparison of lipid profiles and imaging in patients with hyperlipidemia and patients with Sjogren’s syndrome. Am J Roentgenol 2000; 175: 829-834
• 13 Kaltreider HB, Talal N.. Bilateral parotid gland enlargement and hyperlipoproteinemia. JAMA 1969; 210: 2067-2070
• 14 Kohler PF, Winter ME. A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum 1985; 28: 1128-1132
• 15 Kumada M, Kihara S, Sumitsuji S et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89
• 16 Lamey PJ, Darwazeh AM, Frier BM. Oral disorders associated with diabetes mellitus. Diabet Med 1992; 9: 410-416
• 17 Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850
• 18 National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421
• 19 Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476
• 20 Pierce DA, Stram DO, Vaeth M. Allowing for random errors in radiation dose estimates for the atomic bomb survivor data. Radiat Res 1990; 123: 275-284
• 21 Rasouli N, Molavi B, Elbein SC et al. Ectopic fat accumulation and metabolic syndrome. Diabetes Obes Metab 2007; 9: 1-10
• 22 Russotto SB. Asymptomatic parotid gland enlargement in diabetes mellitus. Oral Surg Oral Med Oral Pathol 1981; 52: 594-598
• 23 Ruttmann E, Brant LJ, Concin H et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005; 112: 2130-2137
• 24 Seino Y, Nanjo K, Tajima N et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int; 2010; 1: 2-20
• 25 Sheikh JS, Sharma M, Kunath A et al. Reversible parotid enlargement and pseudo-Sjogren’s syndrome secondary to hypertriglyceridemia. J Rheumatol 1996; 23: 1288-1291
• 26 Sreebny LM, Yu A, Green A et al. Xerostomia in diabetes mellitus. Diabetes Care 1992; 15: 900-904
• 27 Takagi Y, Sumi M, Sumi T et al. MR microscopy of the parotid glands in patients with Sjogren’s syndrome: quantitative MR diagnostic criteria. Am J Neuroradiol 2005; 26: 1207-1214
• 28 Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558
• 29 Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935
• 30 Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295
• 31 Yang WS, Lee WJ, Funahashi T et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819
• 32 Young R, Kerr G. Reassessment of the Atomic Bomb Radiation Dosimetry for Hiroshima and Nagasaki – Dosimetry System 2002. Hiroshima: Radiation Effects Research Foundation; 2005